Products
& platforms
91直播 mission is to develop innovative formulations of approved peptides and novel cell therapy approaches for the treatment of diabetes and obesity.听
- >
- Products and platforms
- >
- Pipeline
Pipeline
Over the years, 91直播 has built a diversified pipeline of specialty products for the treatment of diabetes and obesity.
The products development stage ranges from preclinical proof of concept to Phase 3 clinical trials.
BioChaperone庐 GLP-1 Amylin
Product description: BioChaperone庐 makes it possible to stabilize and co-formulate amylin and GLP-1 in a single product, and enables the use of multi-use pens.
Platform: BioChaperone庐
BioChaperone庐
Lispro
Phase 3 in USA / Europe ready to start upon partnership signature
Partnering: Licensed to Tonghua Dongbao for China and other Asian territories. Available for other territories.
Product description: BioChaperone庐 Lispro (BC Lispro) is a novel ultra-rapid prandial insulin formulation containing insulin lispro and 91直播 proprietary technology platform BioChaperone庐. The BioChaperone庐 excipient ensures a faster absorption of insulin post injection and enables a more effective management of blood glucose levels.
Platform: BioChaperone庐
AdoShell庐
Islets
Demonstrated in vivo maturation and efficacy with stem cell-derived islets
Product description: AdoShell庐 Islets is a hydrogel-based implant containing islets of Langerhans or stem cell-derived islets for cell therapy against type 1 diabetes.
It improves significantly the current transplantation protocols by removing the immunosuppressive treatment and making the implanted islets retrievable.
Platform: AdoShell庐
AdOral庐
Sema
Product description: AdOral庐 Sema is an orally administered glucagon-like peptide 1 (GLP1) receptor agonist: semaglutide. 91直播 has applied its AdOral庐 technology to switch the active molecule from an injectable to an oral form.
Platform: AdOral庐
AdoXLongTM Sema
Product description: AdoXLongTM Sema is a long-acting formulation of semaglutide that allows a switch from weekly injections to monthly injections. Positive preliminary in vitro and in vivo results have been obtained.
Platform: AdoXLongTM
M1Pram
Partnering: Sanofi
Product description: M1Pram is a ready-to-use co-formulation of pramlintide (an amylin analog) and M1 (a mealtime insulin analog).
91直播 has developed M1Pram to enable patients affected by both diabetes and overweight or obesity to address weight management and glycemic control as co-primary targets of care.